Zobrazeno 1 - 10
of 49
pro vyhledávání: '"William J. Brock"'
Autor:
Arianna Bassan, Ronald Steigerwalt, Douglas Keller, Lisa Beilke, Paul M. Bradley, Frank Bringezu, William J. Brock, Leigh Ann Burns-Naas, Jon Chambers, Kevin Cross, Michael Dorato, Rosalie Elespuru, Douglas Fuhrer, Frances Hall, Jim Hartke, Gloria D. Jahnke, Felix M. Kluxen, Eric McDuffie, Friedemann Schmidt, Jean-Pierre Valentin, David Woolley, Doris Zane, Glenn J. Myatt
Publikováno v:
Frontiers in Toxicology, Vol 6 (2024)
The ICH S1B carcinogenicity global testing guideline has been recently revised with a novel addendum that describes a comprehensive integrated Weight of Evidence (WoE) approach to determine the need for a 2-year rat carcinogenicity study. In the pres
Externí odkaz:
https://doaj.org/article/3419c3b90a414f7aafa8e7a2a11aedc0
Autor:
William J. Brock
Publikováno v:
International Journal of Toxicology. 41:420-422
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::585ecd221b470a6f6331d9bd722df026
https://doi.org/10.1177/10915818221106032
https://doi.org/10.1177/10915818221106032
Autor:
David Jones, William J. Brock, Stephanie N Harris, Simon Authier, Wendy G. Halpern, Michael K. Pugsley, Timothy J. McGovern, Pamela D McGovern
Publikováno v:
International Journal of Toxicology. 40:487-505
The growth in drug development over the past years reflects significant advancements in basic sciences and a greater understanding of molecular pathways of disease. Benchmarking industry practices has been important to enable a critical reflection on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c900297e24b5839cdb9dfacb4ba3999f
https://doi.org/10.1177/10915818211043435
https://doi.org/10.1177/10915818211043435
Publikováno v:
Clin Pharmacol Ther
Patients with autosomal dominant polycystic kidney disease (ADPKD) exhibit enhanced susceptibility to tolvaptan hepatotoxicity relative to other patient populations. In a rodent model of ADPKD, the expression and function of the biliary efflux transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4021181d7ad6a4378cc0e2f7f92fe09b
https://doi.org/10.1002/cpt.2007
https://doi.org/10.1002/cpt.2007
Publikováno v:
British journal of pharmacology. 179(7)
Background and purpose Analogues of fibroblast growth factor 21 (FGF21) demonstrate diverse metabolic benefits in preclinical models of type 2 diabetes, dyslipidaemia, and non-alcoholic steatohepatitis (NASH), but clinical responses with different an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb59783989401b048d4ec4cb67f7e3dc
https://pubmed.ncbi.nlm.nih.gov/34773249
https://pubmed.ncbi.nlm.nih.gov/34773249
Autor:
William J. Brock, Jacqueline Bezençon, Katsuaki Ito, Kim L. R. Brouwer, Dong Fu, James J. Beaudoin, Sharin E. Roth
Publikováno v:
Drug Metab Dispos
Autosomal dominant polycystic kidney disease (ADPKD) is a common form of inherited polycystic kidney disease (PKD) and is a leading cause of kidney failure. Fluid-filled cysts develop in the kidneys of patients with ADPKD, and cysts often form in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377dbbc2cf45eebb5b0612854b1f5927
https://doi.org/10.1124/dmd.119.086785
https://doi.org/10.1124/dmd.119.086785
Autor:
Sharin E. Roth, Wei Jia, William J. Brock, Jason R. Slizgi, Kim L. R. Brouwer, Mingming Su, James J. Beaudoin
Publikováno v:
International Journal of Toxicology. 37:144-154
Polycystic kidney disease is characterized by the progressive development of kidney cysts and declining renal function with frequent development of cysts in other organs including the liver. The polycystic kidney (PCK) rat is a rodent model of polycy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c832aeb77b9181c3e2d18a1d24afb2a
https://doi.org/10.1177/1091581818760746
https://doi.org/10.1177/1091581818760746
Autor:
William J Brock
Publikováno v:
Toxicology and industrial health. 35(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca210835381abe567c5382289f8dd4d3
https://pubmed.ncbi.nlm.nih.gov/30862295
https://pubmed.ncbi.nlm.nih.gov/30862295
Autor:
William J. Brock, Robert L. St. Claire, Yang Lu, Jason R. Slizgi, Maxwell Pan, Kenneth R. Brouwer, Kimberly M. Freeman, Kim L. R. Brouwer
Publikováno v:
Drug Metabolism and Disposition. 44:867-870
Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcebc99cb09ed476265f113834c68520
https://doi.org/10.1124/dmd.115.067629
https://doi.org/10.1124/dmd.115.067629
Autor:
William J. Brock, Kim L. R. Brouwer, Katsuhiko Mizuno, Jacqueline Bezençon, Yanguang Cao, Sharin E. Roth, James J. Beaudoin
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 47(2)
Tolvaptan, a vasopressin V2-receptor antagonist, has demonstrated efficacy in slowing kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). In the pivotal clinical trial, the incidence of elevated liver enzyme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7c2375e6fdb4117f420ed03ed72fca
https://pubmed.ncbi.nlm.nih.gov/30772839
https://pubmed.ncbi.nlm.nih.gov/30772839